Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Hiya. Today, we see a proliferation of KRAS, as new data validate a once-undruggable space. Also, a double-edged push for PBM transparency, and the Breakthrough Prize was awarded to researchers for advances in gene therapy and ALS genetics.
The need-to-know this morning
- Novo Nordisk said its experimental oral drug, called etavopivat, reduced the risk of pain crises and improved hemoglobin response in patients with sickle cell disease, achieving the goals of a Phase 3 clinical trial.
- Eli Lilly is reportedly nearing a deal to acquire Kelonia Therapeutics for more than $2 billion, according to the Wall Street Journal. Kelonia is a privately held developer of so-called in-vivo CAR-T therapies that make engineered cancer-killing cells inside the body. Its lead therapy is being investigated in an early stage study in multiple myeloma.
- Helus Pharma, developer of psychedelics-based therapies for depression, said CEO Michael Cola has resigned “at the request of the board of directors.” Chairman Eric So was appointed interim CEO.
Finally cracking KRAS as a druggable target
When Revolution Medicines released results for its drug daraxonrasib in pancreatic cancer patients last week, it finally seemed like there was hope in a condition that has long proven intractable for researchers. But as STAT’s Angus Chen reports, it was the product of years of effort — and could be just the start of a wave of new RAS inhibitors.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
